Research programme: PAR-1 antagonists - Merck

Drug Profile

Research programme: PAR-1 antagonists - Merck

Alternative Names: Research programme: thrombin receptor antagonists - Schering-Plough; SCH 205831; SCH 602539

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co
  • Class
  • Mechanism of Action PAR 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA (IV, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA (PO)
  • 02 Apr 2009 Preclinical development is ongoing in the US with the orally administered PAR-1 antagonists (237th American Chemical Society National Meeting (237th-ACS-2009))
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top